NADAC acquisition cost data for ALBENDAZOLE 200 MG TABLET. This is a generic medication, typically more affordable than brand-name equivalents.
| Generic Name | Albendazole |
| Brand Name | Albendazole 200 mg |
| Manufacturer | Bryant Ranch Prepack |
| Dosage Form | TABLET, FILM COATED |
| Route | ORAL |
| Pharmacologic Class | Anthelmintic |
| Product Type | HUMAN PRESCRIPTION DRUG |
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 70710102108 | $12.91 | 2022-07-20 | Rx |
| 70710102108 | $12.91 | 2022-07-20 | Rx |
| 00115170149 | $13.95 | 2022-12-21 | Rx |
| 00591271202 | $13.95 | 2022-12-21 | Rx |
| 16714090701 | $13.95 | 2022-12-21 | Rx |
| 16714090702 | $13.95 | 2022-12-21 | Rx |
| 31722093502 | $13.95 | 2022-12-21 | Rx |
| 42799011002 | $13.95 | 2022-12-21 | Rx |
| 43598045202 | $13.95 | 2022-12-21 | Rx |
| 69097023772 | $13.95 | 2022-12-21 | Rx |
Generic: Albendazole | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $6.9M | 3,845 | 4,573 | $145.47 |
| 2020 | $9.9M | 5,794 | 5,474 | $129.56 |
| 2021 | $8.0M | 6,932 | 5,864 | $90.48 |
| 2022 | $9.7M | 7,866 | 5,813 | $69.39 |
| 2023 | $10.9M | 9,883 | 7,118 | $60.26 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| New York | $3.8M | 844 | 504 |
| California | $1.7M | 1,006 | 693 |
| Florida | $902.1K | 1,675 | 1,273 |
| Michigan | $778.1K | 329 | 190 |
| New Jersey | $416.9K | 195 | 141 |
| Alabama | $387.1K | 185 | 131 |
| Texas | $308.1K | 729 | 549 |
| Illinois | $240.7K | 194 | 150 |
| Pennsylvania | $239.5K | 347 | 242 |
| Ohio | $136.9K | 287 | 230 |
| Massachusetts | $134.5K | 156 | 109 |
| Georgia | $121.9K | 283 | 225 |
| Minnesota | $114.1K | 102 | 82 |
| Arizona | $106.0K | 154 | 109 |
| Tennessee | $101.9K | 251 | 183 |
| South Carolina | $97.5K | 131 | 107 |
| Missouri | $91.4K | 231 | 158 |
| Virginia | $89.7K | 170 | 137 |
| North Carolina | $89.2K | 279 | 191 |
| Maryland | $85.6K | 122 | 86 |
| Arkansas | $77.4K | 167 | 122 |
| Oklahoma | $67.8K | 172 | 144 |
| Washington | $64.9K | 146 | 123 |
| Nevada | $64.1K | 66 | 43 |
| Colorado | $60.3K | 121 | 83 |
| Kentucky | $59.4K | 174 | 139 |
| Puerto Rico | $55.4K | 114 | 93 |
| Oregon | $54.3K | 105 | 76 |
| Indiana | $48.4K | 131 | 102 |
| Kansas | $46.1K | 64 | 51 |
| Wisconsin | $38.8K | 77 | 59 |
| Connecticut | $37.4K | 87 | 53 |
| Utah | $35.6K | 72 | 51 |
| Louisiana | $34.3K | 111 | 93 |
| New Mexico | $27.4K | 49 | 43 |
| Montana | $22.9K | 39 | 29 |
| Nebraska | $22.6K | 51 | 35 |
| West Virginia | $18.3K | 58 | 48 |
| New Hampshire | $17.7K | 35 | 28 |
| Maine | $17.1K | 49 | 32 |
| Idaho | $16.9K | 49 | 40 |
| Iowa | $16.8K | 61 | 57 |
| Hawaii | $15.3K | 35 | 28 |
| Mississippi | $11.0K | 50 | 37 |
| Delaware | $8.7K | 31 | 23 |
| Rhode Island | $6.9K | 20 | 19 |
| Vermont | $4.7K | 21 | 18 |
| Alaska | $3.9K | 26 | 19 |
| Wyoming | $2.3K | 13 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.